Differential effects of transient treatment of spontaneously hypertensive rats with various antihypertensive agents on the subsequent development of diabetic nephropathy

Nephron - Experimental Nephrology

Volumn 109, Issue 1, 2008, Pages

  Ishiguro, Kimiko ^a   Sasamura, Hiroyuki ^a,b   Sakamaki, Yusuke ^a   Hayashi, Kaori ^a   Saruta, Takao ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetic nephropathy; Spontaneously hypertensive rats; Streptozotocin; Transient antihypertensive treatment

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CANRENOATE POTASSIUM; HYDRALAZINE; MESSENGER RNA; MINERALOCORTICOID ANTAGONIST; N(G) NITROARGININE METHYL ESTER; RENIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; HISTOPATHOLOGY; KIDNEY INJURY; MALE; METABOLIC PARAMETERS; NONHUMAN; PREPUBERTY; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETIC NEPHROPATHIES; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; TREATMENT OUTCOME;

EID: 46349106647     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135386     Document Type: Article

References (21)

1. Friedman EA: Diabetic nephropathy: strategies in prevention and management. Kidney Int 1982;21:780-791.
2. Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P, Lauritzen E: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes. Br Med J (Clin Res Ed) 1988;296:156-160.
3. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-219.
4. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-2033.
5. Strippoli GF, Craig M, Craig JC: Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2005:CD004136.
6. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990;16:603-614.
7. Wu JN, Berecek KH: Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993;22:139-146.
8. Nakaya H, Sasamura H, Hayashi M, Saruta T: Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001;12:659-666.
9. Nakaya H, Sasamura H, Mifune M, Shimizu-Hirota R, Kuroda M, Hayashi M, Saruta T: Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 2002;91:710-718.
10. Ishiguro K, Sasamura H, Sakamaki Y, Itoh H, Saruta T: Developmental activity of the renin-angiotensin system during the 'critical period' modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 2007;30:63-75.
11. Yagi K: Simple procedure for specific assay of lipid hydroperoxides in serum or plasma. Methods Mol Biol 1998;108:107-110.
12. Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R, Saint R, Coutts I, Vickers ME, El Nahas AM, Griffin M: Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 2007;18:3078-3088.
13. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Iwasaki T: Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. Hypertension 2002;40:827-833.
14. Sadee W, Dagcioglu M, Schroder R: Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 1973;185:686-695.
15. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A: Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-711.
16. Baumann M, Hermans JR, Janssen BJ, Peutz-Kootstra C, Witzke O, Heemann U, Smits JF, Boudier HA: Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. J Hypertens 2007;25:2504-2511.
17. Ferrari P, Ferrandi M, Minotti E, Duzzi L, Bianchi G: Effect of canrenone and hydrochlorothiazide on the development of hypertension in rat models of genetic hypertension. J Hypertens 1993;11(suppl):S330-S331.
18. Barret RJ, Buckenheimer TJ, McGuirk BA, Kau ST: Comparative cardiovascular effects of loop-acting, thiazide-type and potassium-sparing diuretics in spontaneously hypertensive rats. Methods Find Exp Clin Pharmacol 1987;9:67-78.
19. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
20. Kambara A, Holycross BJ, Wung P, Schanbacher B, Ghosh S, McCune SA, Bauer JA, Kwiatkowski P: Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J Cardiovasc Pharmacol 2003;41:830-837.
21. Tufro-McReddie A, Romano LM, Harris JM, Ferder L, Gomez RA: Angiotensin II regulates nephrogenesis and renal vascular development. Am J Physiol 1995;269:F110-F115.